Thus, the modified Glasgow Prognostic Score combines CRP and albumin values as a prognostic marker and has been validated in operable and inoperable NSCLC patients but not yet in patients with brain metastases [30, 31]. This evidence concerns the gene ALB and non-small cell lung carcinoma.